Clinical Trial Update: Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating tunlametinib in combination with an anti-EGFR monoclonal antibody for RAS-mutated advanced colorectal and pancreatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer

Drugs mentioned

• Anti-EGFR monoclonal antibody
• Tunlametinib (tunlametinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer | Phase 2 | Status: NOT_YET_RECRUITING